Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorSamsung Medical Center
About this trial
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility criteria
Qualifiers
Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
20 years
Patients requiring systemic chemotherapy with curative intent
Written informed consent
Disqualifiers
Myeloid malignancy
Multiple myeloma
Patients do not require systemic chemotherapy with curative intent
Trial design
Treatments tested in this trial
- Chemotherapy
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
Samsung Medical Center
Lead sponsor
Samsung Genomic Institute
Collaborator
Source ClinicalTrials.gov